Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 2/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 6/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22266501 | 0.96 | GAA (0.48) | GAACES2CYP4F2CYP4A11MEN1 | |
| SCHEMBL22266246 | 0.96 | GAA (0.47) | GAACES2CYP4F2CYP4A11MEN1 | |
| SCHEMBL22266249 | 0.94 | GAA (0.52) | GAACES2CYP4F2CYP4A11MEN1 | |
| SCHEMBL22266234 | 0.93 | GAA (0.50) | GAACES2CYP4F2CYP4A11MEN1 | |
| SCHEMBL22266287 | 0.93 | GAA (0.46) | GAACES2CYP4F2CYP4A11MEN1 | |
| SCHEMBL22374881 | 0.93 | GAA (0.41) | GAACES2CYP4F2CYP4A11MEN1 | |
| SCHEMBL20325133 | 0.93 | GAA (0.50) | GAACES2CYP4F2CYP4A11MEN1 | |
| SCHEMBL22266257 | 0.89 | GAA (0.41) | GAACES2CYP4F2CYP4A11MEN1 | |
| SCHEMBL22266315 | 0.89 | TSHR (0.50) | GAACES2CYP4F2CYP4A11MEN1 | |
| SCHEMBL22374883 | 0.89 | TSHR (0.50) | GAACES2CYP4F2CYP4A11MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10723717-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10723717-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | CRBN, ARAF, VHL | GAA 1531/4885CES2 3556/4885CYP4F2 2758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.